STAT3 and neoplasm: Using in vivo HNSCC mouse models, Moreira et al. showed that a STAT3-inhibiting oligonucleotide linked to CpG specifically targeted to myeloid cells, increased tumor sensitivity to radiotherapy and increased the anti-tumor immune response, suggesting that this could be a valid pathway to target in HNSCC [53].